Clinical Trials | November 14, 2025
Daiichi Sankyo launches first-in-human trial of innovative cancer therapy
The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events
The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events
While the trial fell short of demonstrating a statistically significant PFS benefit compared to chemotherapy, early data suggest a potential overall survival advantage
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
It will produce a comprehensive range of dosage forms including tablets, hard gelatin capsules, liquids, injectables, topicals, and beta-lactam products
Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
The new cGMP-compliant HPAPI Laboratory is equipped with state-of-the-art isolators designed to meet Occupational Exposure Band 5 (OEB-5) requirements
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
Subscribe To Our Newsletter & Stay Updated
